Clinical trials: ESCC
Esophageal Squamous Cell Carcinoma
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
This is a phase 2/window of opportunity study to determine the efficacy, by clinical complete response, and safety of induction toripalimab (PD-1 inhibitor) followed by definitive chemoradiotherapy (dCRT) and adjuvant toripalimab…
- Trial name
- NCT07836049
- Testing
- Toripalimab, Carboplatin + Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma
Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This is a prospective, single-arm, open-label，multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.
- Trial name
- NCT05896787
- Testing
- AK104, nab-paclitaxel, carboplatin
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
- Trial name
- NCT05317325
- Testing
- OCDC vaccine; NeoDC vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Esophageal Squamous Cell Carcinoma (ESCC)
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
This prospective observational study (PKU-ESCC-Monitor) aims to characterize the dynamic evolution of esophageal squamous cell carcinoma (ESCC) using integrated multi-omics, including tissue genomics, ctDNA, imaging features…
- Trial name
- PKU-ESCC (NCT07152535)
- Volunteers
- 255 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Squamous Cell Carcinoma
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying…
- Trial name
- NCT06561178
- Testing
- molecular residual disease detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Esophageal Cancer
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an open-label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03222440
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Neoplasms
A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC
This is a perspective, multicenter,single arm, open study to evaluate the efficacy and safety of treatment with CMNa combined with concurrent chemoradiotherapy in patients with locally recurrent squamous cell esophageal carcinoma…
- Trial name
- NCT02721576
- Testing
- Sodium Glycididazole
- Where
- 9 sites in China
- Volunteers
- 8 people
- Sponsor
- Shandong Cancer Hospital and Institute
Esophageal Cancer
Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma
The purpose of this study is to determine whether the treatment of locally advanced esophageal squamous cell carcinoma (ESCC)with cetuximab in combination with paclitaxel, cisplatin and radiation improve clinical outcomes.
- Trial name
- EXCEL (NCT00815308)
- Testing
- cetuximab (Erbitux), Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Shandong Cancer Hospital and Institute
Esophageal Squamous Cell Carcinoma
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally…
- Trial name
- NCT06420908
- Testing
- Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy
- Sponsor
- Hebei Medical University Fourth Hospital
Squamous Cell Carcinoma of Esophagus
An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma
The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.
- Trial name
- NCT05759325
- Volunteers
- 100 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Esophageal Squamous Cell Carcinoma
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma
- Trial name
- NCT04767295
- Testing
- Camrelizumab, Albumin Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Hunan Cancer Hospital
Esophageal Squamous Cell Carcinoma
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin as neoadjuvant therapy followed by surgery, and pembrolizumab as adjuvant therapy, compared with neoadjuvant…
- Trial name
- KEYSTONE-002 (NCT04807673)
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Esophageal Squamous Cell Carcinoma
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Trial name
- REICRAE (NCT06190652)
- Testing
- Chemotherapy combined with immunotherapy, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 728 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital